Martin Huber
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Martin H.
Huber is currently an Independent Director at Syndax Pharmaceuticals, Inc. since 2021 and an Independent Director at Actuate Therapeutics, Inc. starting in 2026.
Former positions include President, Chief Executive Officer & Director at Mersana Therapeutics, Inc. from 2023 to 2026; President, Head-Research & Development at Xilio Therapeutics, Inc. from 2022 to 2023; Senior Vice President-Clinical at GSK Plc from 2019 to 2020; Chief Medical Officer & Senior Vice President at Tesaro, Inc. from 2015 to 2019; Vice President-Oncology Clinical Research at Merck Research Laboratories Massachusetts LLC from 2012 to 2015; Vice President-Global Pharmacovigilance at Schering-Plough Corp.; Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
Education includes undergraduate studies at Texas Lutheran University and a doctorate from Baylor College of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.03.2026 | 74’000 ( 0.08% ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 15.09.2021 |
| ACTUATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| MERSANA THERAPEUTICS | Vorstandsvorsitzender | 06.01.2026 |
| XILIO THERAPEUTICS, INC. | Präsident | 08.09.2023 |
| GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
| TESARO INC | Technik-/Wissenschafts-/F&E-Leiter | 22.01.2019 |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Corporate Officer/Principal | 01.01.2015 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures antibody drug conjugates to improve patient outcomes in multiple oncology indications | Health Technology |
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for cancer patients | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Texas Lutheran University
Texas Lutheran University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen